Please assess the completion status of the following clinical trial:

Trial Title: Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Biopsy confirmed cervical intraepithelial neoplasia (CIN) 2/3 or 3~  * Planning loop excision or cone biopsy~ * Diagnosis within 2 months prior to study entry~ * Standard histological grading according to Richart~* Visible lesion by colposcopy~  * No unsatisfactory colposcopy or lesions extending into the endocervical canal that cannot be visualized entirely by colposcopy~* No suspicion of invasive cervical cancer by cytology, histology or colposcopy~* No cytologic evidence of glandular atypia or dysplasia~PATIENT CHARACTERISTICS:~* Creatinine normal~* Screening laboratory values within normal range (e.g., complete blood count, liver function tests, renal panel, and electrolytes)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to read and speak English or Spanish~* No known hypersensitivity to bisphosphonates~* Not immunocompromised~* No known HIV positivity~* No aspirin-sensitive asthma due to association of bisphosphonates with bronchoconstriction~* No unexplained abnormal vaginal bleeding~PRIOR CONCURRENT THERAPY:~* No concurrent loop diuretics, aminoglycosides, other nephrotoxic drugs, immunosuppressive drugs, or other investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronate (Type: EXPERIMENTAL): 100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone.
- Saline (Type: PLACEBO_COMPARATOR): 100 cc of saline IV, over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone.

Based on this trial design, predict the completion outcome and termination type (if applicable).